Clinical Trials

236 enrolled

Burkitt Lymphoma, Leukemia

NCT05480449 2026-05-26

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

115 enrolled

Burkitt Lymphoma

NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

155 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT02797470 2026-05-18

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

11 enrolled 9 charts

Plasmablastic Lymphoma, Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, HIV Infections, Lymphoma, T-Cell, Lymphoma, Mantle-Cell

NCT06395103 2026-05-15

MK-9999-01A

90 enrolled

CNSLymphoidSarcoma

Burkitt Lymphoma, Neuroblastoma, Sarcoma, Ewing, Lymphoma, Large B-Cell, Diffuse

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

104 enrolled

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT02362035 2026-05-13

KEYNOTE145

LymphoidOther hematologic neoplasmPlasma cell

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03504644 2026-05-13

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

40 enrolled 18 charts

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03808610 2026-05-13

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

53 enrolled

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07069699 2026-05-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

50 enrolled

Burkitt Lymphoma

NCT07109219 2026-05-11

ALLight

83 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07575919 2026-05-08

Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL

20 enrolled

Burkitt Lymphoma

NCT07575971 2026-05-08

Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

30 enrolled

Burkitt Lymphoma

NCT06287229 2026-04-24

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

40 enrolled

Burkitt Lymphoma, Recurrence

NCT04544592 2026-04-20

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

45 enrolled

Phase 1/2 Not yet recruiting

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell

NCT07313852 2026-04-20

A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia

26 enrolled

Burkitt Lymphoma

NCT04491370 2026-04-15

Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

20 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07523555 2026-04-13

ADAPT-HEM

LymphoidMyeloidOther hematologic neoplasmPlasma cell

96 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04404660 2026-04-08

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

153 enrolled 1 FDA

Burkitt Lymphoma, Recurrence

NCT06533579 2026-03-30

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

32 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05674175 2026-03-27

Co-administration of CART22-65s and huCART19 for B-ALL

93 enrolled

Burkitt Lymphoma

NCT06561425 2026-03-16

Atalanta-1

130 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05255601 2026-02-25

RELATIVITY-069

5 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT06580301 2026-02-06

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

46 enrolled

Burkitt Lymphoma

NCT01371630 2025-12-18

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

276 enrolled

Burkitt Lymphoma

NCT03698552 2025-12-12

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

37 enrolled

Burkitt Lymphoma

NCT03160079 2025-11-10

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

16 enrolled 14 charts

Burkitt Lymphoma, Recurrence

NCT00776373 2025-11-05

UPCC 25406

4 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04035434 2025-10-24

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

93 enrolled 27 charts

Burkitt Lymphoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT05565417 2025-10-16

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

BreastGastrointestinalHead & NeckLymphoidThoracic

67 enrolled

Squamous Cell Carcinoma of Head and Neck, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT03015896 2025-09-29

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

36 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04150497 2025-09-09

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

52 enrolled

Burkitt Lymphoma, Recurrence

NCT05667506 2025-08-12

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

47 enrolled

Burkitt Lymphoma

NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

4 enrolled 8 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06009107 2025-08-08

B-ALL

Phase 1/2 Not yet recruiting

Burkitt Lymphoma

NCT06703216 2025-06-15

PACER

24 enrolled

Phase 1/2 Not yet recruiting

Cytokine Release Syndrome, Burkitt Lymphoma

NCT07020260 2025-06-13

PACMAN

18 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma

NCT06735495 2024-12-16

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

80 enrolled

Burkitt Lymphoma, Lymphoma, Recurrence

NCT06635330 2024-10-10

Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL

5 enrolled

Burkitt Lymphoma, Recurrence

NCT01998035 2024-08-22

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

DermatologicLymphoidOther hematologic neoplasm

58 enrolled 11 charts

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06503094 2024-07-16

CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors

80 enrolled

Burkitt Lymphoma, Lymphoma, Recurrence

NCT05936229 2024-07-12

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT05310591 2024-05-29

CAPTiRALL

26 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00863369 2024-03-20

Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

33 enrolled 14 charts

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05613348 2024-03-18

CAR19T2

Burkitt Lymphoma, Lymphoma, Lymphoma, B-Cell

NCT00031642 2023-12-27

Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation

26 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04029038 2023-08-21

Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Disease Progression

NCT00788125 2023-07-14

Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors